DownloadDate: October 9th, 2019
Presented by: Ken Phelps, president and co-founder, Camargo
In orphan drug development, smaller patient populations present unique challenges when it comes to demonstrating safety and efficacy to support regulatory approval. Similarly, 505(b)(2) drug development by definition utilizes publicly available data sources to support approval.
In this webinar, we’ll share insights to harness the strategic value of real world data to build optimized drug development programs that minimize the time and cost of sponsor-driven studies.